Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to investigate the utility and effectiveness of a decision aid in cisplatin-intolerant patients with locally advanced cervical cancer. The main questions it aims to answer are: 1. What is the effectiveness of the decision aid in reducing decisional conflict? 2. What is the utility of the decision aid in preparing for decision-making? Participants will be asked to accomplish the Decisional Conflict Scale before and after using the decision aid. Researchers will compare patients given routine care and the decision aid with patients given routine care to see if the decision aid reduces decisional conflict.


Clinical Trial Description

In locally advanced cervical cancer (LACC), adding chemotherapy (ChT) to radiotherapy (RT) improves survival at the cost of increased toxicity. Among patients with cisplatin contraindications, compliance to RT may be compromised. Shared decision-making (SDM) allows for more patient engagement in the decision-making process and decision implementation planning. In cancer-related decision-making, patient decision aids (PtDA) facilitate the SDM process and have increased patient knowledge and satisfaction and decreased decisional conflict and attitudinal barriers improved patient satisfaction and treatment compliance. The CECIL study is a two-phase study to develop, validate and test the effectiveness of a PtDA for cisplatin-intolerant LACC patients faced with the decision of adding ChT to RT. Phase 1 is a mixed-methods study to develop a PtDA prototype and determine its content validity and user acceptability. Phase 2 is a block-randomized clinical trial to determine its effectiveness in reducing decisional conflict and its utility in preparing for decision-making. Adult women with biopsy-proven untreated LACC with cisplatin contraindications will be included in this trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05701735
Study type Interventional
Source University of Santo Tomas Hospital, Philippines
Contact Warren Bacorro, MD
Phone +639171665927
Email warren.bacorro.gs@ust.edu.ph
Status Recruiting
Phase N/A
Start date February 20, 2023
Completion date December 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06398938 - Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy
Recruiting NCT05406856 - PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer N/A
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05462379 - Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. Phase 1/Phase 2
Recruiting NCT05235516 - A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer Phase 3
Not yet recruiting NCT05210270 - HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy Phase 1/Phase 2
Recruiting NCT05722288 - Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers Phase 2
Recruiting NCT06391190 - Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT06378840 - the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer
Recruiting NCT05975593 - MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Recruiting NCT06349642 - Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
Not yet recruiting NCT04789941 - How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix Phase 2